SARS-CoV-2新型抗原快速诊断的准确性:一项动态系统评价与荟萃分析
该动态系统评价与荟萃分析评估了商用SARS-CoV-2抗原快速诊断测试(Ag-RDT)的临床准确性,纳入133项研究共112,323份样本。汇总灵敏度为71.2%(95%CI 68.2%–74.0%),特异度为98.9%(95%CI 98.6%–99.1%);症状出现第一周内灵敏度达83.8%,高病毒载量(Ct<20)时灵敏度为96.5%。Ag-RDT在病程早期和高病毒载量人群中检测效用高。
要点
- Ag-RDT汇总灵敏度71.2%、特异度98.9%,特异性极高。
- 症状出现第一周内灵敏度83.8%,高病毒载量(Ct<20)时达96.5%。
- 遵循制造商说明可提高灵敏度至76.3%,前鼻取样灵敏度75.5%。
核心结论
- Ag-RDT在症状出现第一周内及高病毒载量人群中能检出绝大多数SARS-CoV-2感染者,适用于疾病早期诊断。
研究设计与样本
- 动态系统评价与荟萃分析,检索截至2021年4月30日,纳入133项分析和临床研究,共214个临床准确性数据集、112,323份样本,以RT-PCR为参照。
主要发现
- 汇总灵敏度71.2%(95%CI 68.2%–74.0%),特异度98.9%(95%CI 98.6%–99.1%)。
- 遵循制造商说明时灵敏度76.3%(95%CI 73.1%–79.2%)。
- Ct<20时灵敏度96.5%(95%CI 92.6%–98.4%),Ct<25时95.8%(95%CI 92.3%–97.8%),Ct≥25时50.7%(95%CI 35.6%–65.8%),Ct≥30时20.9%(95%CI 12.5%–32.8%)。
- 症状出现第一周内灵敏度83.8%(95%CI 76.3%–89.2%),一周后61.5%(95%CI 52.2%–70.0%)。
- 前鼻取样灵敏度75.5%(95%CI 70.4%–79.9%),鼻咽取样71.6%(95%CI 68.1%–74.9%)。
关键数值与推荐
- LumiraDx灵敏度最高,为88.2%(95%CI 59.0%–97.5%)。
- 非仪器Ag-RDT中Standard Q鼻拭子表现最佳,灵敏度80.2%(95%CI 70.3%–87.4%)。
- 24.1%的数据集报告了制造商资助。
临床怎么用
- Ag-RDT适用于症状出现第一周内的早期诊断和高病毒载量人群的快速筛查。
- 检测时应遵循制造商说明,并优先选择前鼻取样以提高灵敏度。
局限性
- 纳入研究在设计和方法学上存在异质性。
- 所有数据集均存在偏倚风险担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs. METHODS AND FINDINGS: We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until 30 April 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcription polymerase chain reaction (RT-PCR) testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS-2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy datasets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity and specificity were 71.2% (95% CI 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively. Sensitivity increased to 76.3% (95% CI 73.1% to 79.2%) if analysis was restricted to studies that followed the Ag-RDT manufacturers' instructions. LumiraDx showed the highest sensitivity, with 88.2% (95% CI 59.0% to 97.5%). Of instrument-free Ag-RDTs, Standard Q nasal performed best, with 80.2% sensitivity (95% CI 70.3% to 87.4%). Across all Ag-RDTs, sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values, i.e., <20 (96.5%, 95% CI 92.6% to 98.4%) and <25 (95.8%, 95% CI 92.3% to 97.8%), in comparison to those with Ct ≥ 25 (50.7%, 95% CI 35.6% to 65.8%) and ≥30 (20.9%, 95% CI 12.5% to 32.8%). Testing in the first week from symptom onset resulted in substantially higher sensitivity (83.8%, 95% CI 76.3% to 89.2%) compared to testing after 1 week (61.5%, 95% CI 52.2% to 70.0%). The best Ag-RDT sensitivity was found with anterior nasal sampling (75.5%, 95% CI 70.4% to 79.9%), in comparison to other sample types (e.g., nasopharyngeal, 71.6%, 95% CI 68.1% to 74.9%), although CIs were overlapping. Concerns of bias were raised across all datasets, and financial support from the manufacturer was reported in 24.1% of datasets. Our analysis was limited by the included studies' heterogeneity in design and reporting. CONCLUSIONS: In this study we found that Ag-RDTs detect the vast majority of SARS-CoV-2-infected persons within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease, making them a valuable tool to fight the spread of SARS-CoV-2. Standardization in conduct and reporting of clinical accuracy studies would improve comparability and use of data.
引用
- Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med. 2021. PMID: 34383750. doi:10.1371/journal.pmed.1003735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。